Furthermore, recently, the efficacy of nivolumab (Niv), a fully human monoclonal immunoglobulin G4 antibody to programmed cell death-1 (PD-1), plus ipilimumab (Ipi), a fully humanized IgG1 monoclonal antibody to cytotoxic T lymphocyte antigen-4 (CTLA-4), as a combination therapy (Niv+Ipi) in programmed cell death ligand 1 (PD-L1)-positive previously untreated advanced NSCLC has been reported [11]. Here, PDCD1 is linked to non-small cell lung carcinoma.